Saturday 17 October 2026
Export BIVI’s income statement to Excel — free account
BioVie Inc.
BIVI Healthcare Biotechnology
In the quarter to June 2026, EPS fell 209.1% and free cash flow grew 26.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.20
0.07
+6.19%
Follow BIVI
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 1,750.00 | 150.00 | 263.75 | 220.00 | 436.00 | 132.50 | 113.80 | 10.40 | 1.10 | 0.82 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | 5,625.00 | 3,125.00 | 1,750.00 | 3,454.00 | 4,609.80 | 1,438.00 | 1,139.00 | 331.00 | 25.76 | 3.79 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 2 | 2 | 13 | 18 | 14 | 13 | 13 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (1) | (2) | (2) | (17) | (130) | (26) | (50) | (32) | (18) | (22) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (1) | (2) | (2) | (17) | (130) | (26) | (50) | (32) | (18) | (22) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (1.25) | (3.75) | (96.23) | (685.00) | (1,482.00) | (106.00) | (155.00) | (73.00) | (12.12) | (3.05) | |||||
| Cash flow | (0.87) | (0.81) | (98.49) | (33.03) | (84.30) | (77.01) | (123.93) | (61.84) | (12.88) | (2.63) | |||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (0.87) | (0.81) | (98.49) | (33.03) | (84.30) | (77.01) | (123.93) | (61.84) | (12.88) | (2.63) | |||||
| Book value | 1.62 | 0.15 | 83.89 | (436.08) | 40.73 | 14.89 | 47.23 | 34.31 | 12.87 | 1.42 | |||||
| Shares, m | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (1) | (1) | (3) | (2) | (10) | (19) | (40) | (28) | (19) | (19) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | (1) | (1) | (3) | (2) | (10) | (19) | (40) | (28) | (19) | (19) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | (1) | (1) | 0 | (23) | 4 | 15 | 20 | 15 | 18 | 10 | ||||
| Total debt | 0 | 1 | — | 1 | — | 12 | 5 | — | — | — | |||||
| Net debt | 0 | 1 | 0 | 1 | (5) | (7) | (29) | (24) | (18) | (9) | |||||
| Shareholders’ equity | 1 | 0 | 2 | (21) | 5 | 4 | 15 | 16 | 19 | 10 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (52.35) | (107.24) | (104.97) | (1,450.13) | (4,522.36) | (199.41) | (182.02) | (109.45) | (76.59) | (123.51) | ||||
| ROIC | 0.00 | 0.00 | (87.12) | 0.00 | (16,017.04) | 0.00 | 0.00 | 0.00 | (769.48) | (1,095.00) | |||||
| ROE | (86.60) | (383.78) | (222.37) | 348.78 | 2,235.46 | (598.19) | (528.70) | (214.01) | (103.78) | (151.06) | |||||
Negative figures in brackets.
Charts ten years each
BioVie Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GDTC CytoMed Therapeutics Limited | $10.3M | — (loss-making) | — (loss-making) | — | n/m | −27.39% (below 0%: shrinking) | 0.00% | — | Compare |
| BLRX BioLineRx Ltd. | $10.2M | — (loss-making) | — (loss-making) | −3.29% (below 0%: shrinking) | n/m | −1,827.71% (below 0%: shrinking) | 79.93% | (1,215.31%) | Compare |
| LTRN Lantern Pharma Inc. | $10.0M | — (loss-making) | — | — | n/m | +25.31% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TOVX Theriva Biologics, Inc. | $9.7M | 0.1× | — | +33.08% (above 0%: growing) | n/m | +34.69% (above 0%: growing) | 100.00% | 0.00% | Compare |
| BIVI BioVie Inc. | $9.6M | — (loss-making) | — | — | n/m | +26.50% (above 0%: growing) | 0.00% | 0.00% | |
| LSTA Lisata Therapeutics, Inc. | $9.6M | — (loss-making) | — (loss-making) | −98.30% (below 0%: shrinking) | n/m | +33.04% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VTGN VistaGen Therapeutics, Inc. | $9.5M | — (loss-making) | — (loss-making) | +504.92% (above 0%: growing) | n/m | +22.23% (above 0%: growing) | 100.00% | (904.34%) | Compare |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR | $9.4M | — (loss-making) | — | — | n/m | +47.89% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MTVA MetaVia Inc. | $9.0M | — (loss-making) | — | — | n/m | −22.42% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $9.7M | — | — | +14.90% | — | +23.77% | 79.93% | 0.00% |
BioVie Inc. (BIVI) key facts
- BioVie Inc. (BIVI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, BIVI traded at $1.20, a market capitalization of $9.6 million.
- Return on equity was −151.1% and debt-to-equity 0.00.
BioVie Inc. (BIVI) Latest News
No news at this impact. Lower the threshold for more.